推荐产品
等级
pharmaceutical primary standard
API类
atomoxetine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl
InChI
1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
InChI key
LUCXVPAZUDVVBT-UNTBIKODSA-N
基因信息
human ... SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
一般描述
本品按现行药典规定交付。该产品的所有支持信息，包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持，请见现行药典的网站。
应用
盐酸阿托西汀EP参考标准品的预期用途是欧洲药典规定的实验室测试。
生化/生理作用
去甲肾上腺素摄取阻滞剂。
包装
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
其他说明
可能适用相应的销售限制。
相关产品
产品编号
说明
价格
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ATOMOXETINE HYDROCHLORIDE IN BULK AND CAPSULE DOSAGE FORM BY RP-HPLC.
Swathi G, et al.
World Journal of Pharmacy and Pharmaceutical Sciences (2015)
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, et al.
European Neuropsychopharmacology, 19(11), 822-834 (2009)
Irene Joy I Dela Peña et al.
Progress in neuro-psychopharmacology & biological psychiatry, 88, 311-319 (2018-08-21)
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterized by varying levels of hyperactivity, inattention, and impulsivity. Patients with ADHD are often classified as (1) predominantly hyperactive-impulsive, (2) predominantly inattentive, and (3) combined type. There is a growing interest in
Addressing the unique issues of student athletes with ADHD.
Adam E Perrin et al.
The Journal of family practice, 63(5), E1-E9 (2014-05-06)
Atomoxetine-induced mydriasis in a child patient.
Kayhan Bahali et al.
European child & adolescent psychiatry, 23(12), 1231-1232 (2013-11-12)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门